Open search

Search suggestion

Open suggestion box

Search suggestion

See related products

Kluwer Patent Blog

Search filters

Clear all

GENERAL PREFERENCES

Sort by

Search

Search only titles

Jurisdiction

Spain (194)

France (0)

Germany (0)

Poland (0)

Netherlands (0)

Bulgaria (0)

United Kingdom (0)

Denmark (0)

Belgium (0)

European Union (0)

Italy (0)

Austria (0)

United States of America (0)

Estonia (0)

Greece (0)

Switzerland (0)

Sweden (0)

Norway (0)

Slovenia (0)

Lithuania (0)

Czech Republic (0)

Hungary (0)

Finland (0)

China (0)

Australia (0)

Portugal (0)

Latvia (0)

India (0)

Russia (0)

Ireland (0)

Ukraine (0)

Turkey (0)

Brazil (0)

South Africa (0)

Japan (0)

Canada (0)

Mexico (0)

New Zealand (0)

Argentina (0)

Saudi Arabia (0)

Singapore (0)

EPC (0)

Tags

Bolar provision (2)

Case Law (2)

claim construction (2)

Spain (2)

Andorra (1)

bad faith (1)

burden of proof (1)

Contributory infringement (1)

Doctrine of equivalents (1)

EPO (1)

fingolimod (1)

Generics (1)

mechanical patent (1)

obviousness (1)

patent (1)

Patent prosecution estoppel (1)

Preliminary Injunction (1)

Protocol of Interpreation of article 69 EPC (1)

Second Medical Use (1)

territorial jurisdiction (1)

TRIPS (1)

unfair competition (1)

UPC (1)

Pharmaceuticals (0)

CPC (0)

escitalopram (0)

Directive 2004/48 (0)

Imminent infringement (0)

Marketing authorization (0)

Denmark (0)

equivalence (0)

luggage ramp (0)

SAS (0)

Inventive step (0)

Mechanical Engineering (0)

Novelty (0)

Validity (0)

PI (0)

settlement (0)

bifurcation (0)

infringment action (0)

nullity action (0)

Scope of protection (0)

separation (0)

ex parte (0)

ratiopharm (0)

reversed burden of proof (0)

local jurisdictions (0)

Community Patent (0)

European Patent Litigation (0)

Harmonisation (0)

Multinational litigation (0)

Revocation (0)

divisionals (0)

res iudicata (0)

Kreiselegge II (0)

Raffvorhang (0)

same or similar act (0)

Lundbeck (0)

SPC (0)

International Judges Conference (0)

Added Matter (0)

Art. 123(2) EPC (0)

Comprising-consisting (0)

interlocutory injunction (0)

marketing authorisation (0)

enforcement (0)

procedural matters (0)

Swiss Federal Patent Court (0)

costs (0)

supreme court (0)

Court of Justice of the European Union (0)

hESCs (0)

Harnkatheterset (0)

trade show (0)

undisputed patent (0)

Translation Requirement (0)

America Invents Act (0)

Patent Reform (0)

U.S. Patent Office (USPTO) (0)

infringment (0)

prosecution file (0)

20 Year Term (0)

Patent Term Adjustment (PTA) (0)

Wyeth (0)

CJEU; Medimmune; Novartis Pharmaceuticals (0)

America Invents Act (AIA) (0)

First To File (0)

Post Grant Review (0)

Secret Prior Art (0)

Discovery (0)

Evidence (0)

License (0)

Negotiations (0)

Privilege (0)

Reasonable Royalty (0)

ANDA (0)

Bayer (0)

Caraco (0)

Generic (0)

Hatch Waxman (0)

Orange Book (0)

Paragraph IV (0)

Prandin (0)

Repaglinide (0)

U.S. Supreme Court (0)

Yasmin (0)

utility models (0)

Obviousness Type Double Patenting (0)

Patent Term (0)

Terminal Disclaimer (0)

Myriad (0)

Personalized Medicine (0)

Prometheus (0)

litigation (0)

opposition (0)

patents (0)

Amphastar (0)

Enoxaparin (0)

FDA (0)

Lovenox (0)

Momenta (0)

Safe Harbor (0)

ACLU (0)

BRCA (0)

Breast Cancer (0)

Gene Patent (0)

Isolated DNA (0)

Applicant (0)

Inter Partes Review (0)

Inventor Oath/Declaration (0)

biotech (0)

infringement (0)

sufficient disclosure (0)

Medeva Sanofi SPC injunction (0)

Preissuance Submissions (0)

Prior Art (0)

Protest (0)

Third-Party Submissions (0)

PCC (0)

Patent-Eligibility (0)

invalidity (0)

technical feature (0)

inspection order (0)

third party (0)

Jurisdiction (0)

BGH (0)

data (0)

DVD (0)

encoding (0)

exhaustion (0)

MPEG-2 (0)

product directly obtained by a process (0)

test purchase (0)

video data (0)

Product Of Nature (0)

35 USC 101 (0)

Abstract Idea (0)

Alice Corporation (0)

CLS Bank (0)

human embryonic stem cells (0)

Non Practicing Entities (0)

Non Practicing Entity (0)

Patent Assertion Entities (0)

Patent Assertion Entity (0)

Patent Trolls (0)

White House (0)

Baxter (0)

Covered Business Method (0)

Fresenius (0)

Reexamination (0)

SAP (0)

Versata (0)

FRAND (0)

Patent Tertm Adjustment (0)

1977 UK Patents Act (0)

microcontroller (0)

smart card (0)

telecommunications (0)

referendum (0)

doctrine of equivalanet (0)

Innovation Act (0)

Goodlatte Innovation Act (0)

Leahy Patent Transparency And Improvements Act (0)

Exelixis (0)

Novartis (0)

Request For Continued Examination (RCE) (0)

amendments (0)

intermediate generalization (0)

Patent Trial And Appeal Board (PTAB) (0)

Patent Subject Matter Eligibility (0)

Attributable Owner (0)

Real Party In Interest (0)

Ultimate Parent Entity (0)

Clones (0)

Dolly (0)

back reference (0)

Europe (0)

France (0)

Representation (0)

UK (0)

Infringement; Declaratory Interest; NDA (0)

biased judge (0)

EPO organisation unconstitutional (0)

partiality (0)

euqivalence (0)

BGH X ZU 36/13 (0)

doctrine of equivalence (0)

Arbitration (0)

EU competition law (0)

License agreeement (0)

CJEU (0)

Court of Appeals (0)

Federal Circuit (0)

US (0)

Ajinomoto (0)

Conservatory measures (0)

Counterfeit (0)

Italy (0)

Michele di Sciuva (0)

Unitary Patent (0)

Nokia (0)

Richard Vary (0)

renewal fees (0)

cooking pan (0)

doctrine of eqivalence (0)

Kochgefäß (0)

side-effect (0)

X ZR 81/13 (0)

Benoit Battistelli (0)

Netherlands (0)

Wouter Pors (0)

Business Europe (0)

Eurochambres (0)

Transit proceedings (0)

Piercing the corporate veil (0)

copyright (0)

Ctm (0)

government (0)

ohim (0)

trade mark (0)

Beijing Treaty (0)

EC (0)

intergovernmental organisations (0)

Marrakesh Treaty (0)

trade (0)

WIPO (0)

WTO (0)

Examination report (0)

UKIPO (0)

EU (0)

injunction (0)

Canada (0)

international treaties (0)

Japan (0)

judicial review (0)

mediation (0)

district court (0)

term (0)

USA (0)

Australia (0)

ECHR (0)

experts (0)

hot-tubbing (0)

insight (0)

IPEC (0)

Ireland (0)

judges (0)

judiciary (0)

procedure (0)

competition (0)

innovation (0)

EPC 2000 (0)

swiss-style (0)

assignment (0)

employee (0)

priority (0)

title (0)

licensing (0)

royalty (0)

transactions (0)

valuation (0)

amino acids (0)

antibodies (0)

antibody (0)

biologic (0)

biosimilar (0)

BPCIA (0)

protein (0)

AIA (0)

amendment (0)

construction (0)

EPC (0)

Markman (0)

post-grant (0)

PTAB (0)

USPTO (0)

genes (0)

patentability (0)

section 101 (0)

software (0)

technical (0)

Patent Quality (0)

European Commission (0)

Competition law (0)

Akamai (0)

Direct Infringement (0)

Limelight (0)

Good faith (0)

European Union (0)

Finland (0)

Czech Republic (0)

Slovakia (0)

algorithm (0)

firmware (0)

inactivated feature (0)

patent infringement (0)

sleeping feature (0)

Catalonia (0)

independence (0)

Russia (0)

Scotland (0)

Unjustified threats (0)

Kyle Bass (0)

Damages (0)

Interim Injunction (0)

EPLIT (0)

SMEs (0)

IP Ownership (0)

European (0)

United Kingdom (0)

exhibition (0)

trade fair (0)

Antitrust (0)

Industrial Property (0)

Rules of procedure (0)

Brexit (0)

Clarity (0)

Protective Letter (0)

Productivity Commission (0)

Quizz (0)

fair basis (0)

GlaxoSmithKline (0)

Omnibus (0)

Reckitt (0)

floating charge (0)

pledge (0)

security interests (0)

computer programming (0)

gaming machine (0)

IP Australia (0)

RPL Central (0)

Diglycidverbindung (0)

Improver (0)

Okklusionsvorrichtung (0)

Pemetrexed (0)

Court Fees (0)

Actavis (0)

Apotex (0)

exclusive licence (0)

orion (0)

Patents Act 1990 (0)

Biosimilars (0)

AIPPI (0)

co-inventorship (0)

Full Federal Court of Australia (0)

inventive concept (0)

inventorship (0)

PCT application (0)

provisional application (0)

Rule of Law (0)

draft legislation (0)

extension of time (0)

Quiz (0)

Germany (0)

business method (0)

evergreening (0)

fees (0)

IP Arrangements (0)

Patents Act (0)

pay-for-delay (0)

AIDS (0)

compulsory license (0)

drugs (0)

federal patent court (0)

HIV (0)

Merck (0)

pharmaceutical (0)

rospatt (0)

Shinogi (0)

Zwangslizenz (0)

Federal Court of Australia (0)

Generic Health (0)

Isabelle (0)

post-tax loss (0)

pre-tax loss (0)

substitutability (0)

Britax (0)

Coretell (0)

date of patent (0)

filing (0)

grant (0)

innovation patents (0)

Mud (0)

exploit (0)

Lyrica (0)

offer (0)

PBS listing (0)

Pharmaceutical Benefits Scheme (0)

pregabalin (0)

Warner-Lambert (0)

UPCA ratification (0)

Estonia (0)

law reform (0)

objects clause (0)

Antonio Campinos (0)

UPCA (0)

Analytics (0)

IPR (0)

Boards of Appeal (0)

quality (0)

efficiency (0)

vision (0)

judicial independence (0)

Administrative Council (0)

trust (0)

clinical trials (0)

76A (0)

innovation patent (0)

Battistelli (0)

human rights (0)

freedom of contract (0)

technology transfer (0)

University inventions (0)

passing-off (0)

Competition Act (0)

Licence (0)

reform (0)

trade practices (0)

Medical Devices (0)

Artificial Intelligence (0)

Machine Learning (0)

plant variety (0)

Dependent claims; search; prosecution (0)

constitutional complaint (0)

trademark (0)

machine (0)

Switzerland (0)

repeal (0)

Tenofovir (0)

Confidential (0)

German Federal Patent Court (0)

guidelines (0)

royalty rate (0)

enablement (0)

book review (0)

visser (0)

Ethiopia (0)

Food (0)

Biogen insufficiency (0)

Classical insufficiency (0)

European Patent Convention (0)

European Patent Office (0)

Kimberly-Clark (0)

plausibility (0)

undue burden (0)

Bundespatentgericht (0)

District Court of The Hague (0)

invalidation (0)

preliminary injunctions (0)

A Practitioner's guide to Supplementary Protection Certificates in Europe (0)

Alexa von Uexküll (0)

Oswin Ridderbusch (0)

examination (0)

flexible timing (0)

speed (0)

Google (0)

non-technical features (0)

patent application (0)

trade secrets (0)

Board of Appeal (0)

Haar (0)

Munich (0)

Traveling Circus (0)

financial sustainability (0)

Cyprus (0)

International Preliminary Examination (0)

Re-establishment of rights (0)

implied licence (0)

Menck (0)

FRAND licences (0)

Hetti Hilge (0)

prior use right (0)

rospatt osten pross (0)

nonbviousness (0)

surgical devices (0)

EQE (0)

181 patent (0)

dosage patent (0)

PACTE law (0)

RPBA (0)

patent litigation (0)

saisie contrefaçon (0)

sub-ranges (0)

Problem Inventions (0)

Ericsson (0)

SEPs (0)

TCL Communication Technology Holdings Ltd. (0)

abridged form of decision (0)

Art. 15(9) RPBA (0)

Rules of Procedure of the Boards of Appeal (RPBA) (0)

Alternatives (0)

Enhanced Damages (0)

Willful Blindness (0)

Covid-19 (0)

epi (0)

SSOs (0)

Ghent Business Court (0)

opposition fee (0)

Hugo Meinders (0)

Rules of Procedure of the Boards of Appeal (0)

Global Patent Strategy (0)

Patent Strategy (0)

patentable (0)

Closest Prior Art (0)

Problem-Solution-Approach (0)

user-friendly (0)

Daimler AG (0)

Mercedes-Benz (0)

royalties (0)

ezetimibe (0)

ezetimibe-simvastatine (0)

reformatio in peius (0)

Eli Lilly (0)

Business model (0)

Patent protection (0)

Value proposition (0)

anti-suit injunction (0)

EPC 138/3 (0)

ETSI (0)

European Telecommunications Standards Institute (0)

Huawei (0)

je t'aime moi non plus (0)

Unwired Planet (0)

trademarks (0)

Board op Appeal (0)

ViCo (0)

videoconferencing (0)

AASI (0)

TRUVADA (0)

Hutchinson (0)

SPC Waiver Regulation (0)

Standard-Setting Organisations (SSOs). (0)

training (0)

Democracy (0)

novelty assessment (0)

sufficiency of disclosure (0)

Amgen’s Repatha (0)

Sanofi’s Praluent (0)

Transparency of Declarations (0)

Comparable licenses approach (0)

Conversant vs ZTE/Huawei (0)

Philips vs TCL (0)

Top Down Approach (0)

TQ Delta v ZyXel or Optis v Apple (0)

Unwired Planet vs Huawei (0)

New Normal (0)

Nemo Iudex (0)

Warning letter (0)

International Law Talk (0)

Patent settlements (0)

Patent Act (0)

Community Design (0)

Patent term extension (0)

Patent linkage (0)

PRC patent (0)

Investment Treaty Arbitration (0)

Patent breaking (0)

TRIPS COVID-19 Waiver (0)

Value in Dispute (0)

Delaware District Court (0)

Hatch-Waxman Act (0)

U.S. Court of Appeals (0)

Inventor (0)

Amicus Brief (0)

SUEPO (0)

Enlarged Board of Appeal (0)

oral proceedings (0)

video conference (0)

Food and Drug Administration (0)

United States Patent and Trademark Office (0)

Foundation for a Smoke-Free World (0)

Smoking (0)

Tobacco (0)

Tobacco harm-reduction patents (0)

Patent Trial and Appeal Board (0)

Post Grant Review (PGR) (0)

nullity proceedings (0)

Alternative dispute resolution (ADR) (0)

Federal Trade Commission (0)

organization (0)

limitation period (0)

refund (0)

licensing negotiation process (0)

predictability (0)

predictability of domestic litigations (0)

transparency (0)

Exclusive patent license (0)

Medicine (0)

International Organization for Standardization (0)

Standard Setting Organizations (0)

Statistics (0)

History (0)

ILOAT (0)

government policy (0)

top 3 (0)

common interest (0)

communication (0)

pharma patent (0)

proportionality defense (0)

buildings (0)

EUIPO (0)

code of conduct (0)

2023 edition (0)

Annotated European Patent Convention (0)

unity of invention (0)

5G (0)

RNA Law (0)

Arkyne (0)

Florence Butin (0)

Local division UPC The Hague (0)

Plant-e (0)

Amazon (0)

multimedia (0)

reforms (0)

Beat Weibel (0)

IPQC (0)

call for papers (0)

London (0)

PhD (0)

CMS UPC (0)

Legal Team functionality (0)

CMS functionalities (0)

Sir Robin Jacob (0)

procedural language (0)

devolutive effect (0)

top ten 2023 (0)

Bristows (0)

Mathys & Squire (0)

divisional (0)

IBEC (0)

Neale Richmond (0)

North Macedonia (0)

Milan (0)

UPC central division (0)

European Parliament (0)

NGT (0)

plants (0)

Alexander Ramsay (0)

Irish referendum (0)

10xGenomics (0)

NanoString (0)

UPC Court of Appeal (0)

Translators (0)

AR (0)

Metaverse (0)

Technology (0)

VR (0)

XR (0)

Manual IP (0)

MIP (0)

sustainability (0)

welfare (0)

Andean Community (0)

Bolivia (0)

description (0)

Christmas (0)

European Union; FRAND (0)

SEP (0)

use claim (0)

claim interpretation (0)

G1/24 (0)

Bolar Exception (0)

appellate review (0)

UK Supreme Court (0)

dimethyl fumarate (0)

presumption of validity (0)

best method requirement (0)

Contributor

Miquel Montañá (155)

Adrian Crespo (35)

Brian Cordery (1)

Dr. Ingve Björn Stjerna (1)

Kluwer Patent blogger (1)

Pieter Callens (1)

Bruno Weil (0)

Anja Lunze (0)

Mark Einerhand (0)

Krystyna Szczepanowska-Kozlowska (0)

Peter Burgers (0)

Lars de Haas (0)

Ivan Marinov (0)

Mark van Gardingen (0)

Sam Tuxford (0)

Bart van Weezenbeek (0)

Clemens Rübel (0)

Peter-Ulrik Plesner (0)

Robert Burrows (0)

Florence Verhoestraete (0)

Ferry van Looijengoed (0)

Daan de Lange (0)

Klaas de Vries (0)

Marjanka Vermunt (0)

Christian Gassauer-Fleissner (0)

Iustina Grigordiadis (0)

Rik Lambers (0)

Pierre Véron (0)

Korbinian Kopf (0)

Daniela Ampollini (0)

Erik Visscher (0)

Ruprecht Hermans (0)

Thomas Musmann (0)

Kristof Roox (0)

Derk Visser (0)

Anders Valentin (0)

Martin Hohgardt (0)

Olivier Moussa (0)

Tobias Hahn (0)

Eike Schaper (0)

Kaja Veel Midtbø (0)

Eleni Lappa (0)

Henrik Timmann (0)

Bernward Zollner (0)

Simon Holzer (0)

Giovanni Gozzo (0)

Thorsten Bausch (0)

Jochen Buehling (0)

Rüdiger Pansch (0)

Hetti Hilge (0)

Markus Lenssen (0)

Maja Bogataj Jančič (0)

Mindaugas Kiskis (0)

Gustav Bacher (0)

Stephan von Petersdorff-Campen (0)

Richard Ebbink (0)

Andri Hess (0)

Lars Erik Steinkjer (0)

Andrew Sharples (0)

Robert Fitt (0)

Courtenay C. Brinckerhoff (0)

Robert Lundie Smith (0)

Emmanuel Gougé (0)

Shane O'Brien (0)

Simon Klopschinski (0)

Niels Hölder (0)

Thomas Becher (0)

Matthew Blaseby (0)

Theofanis Salatas (0)

Tamara Elmore (0)

Johanna Lilja (0)

Laurence Brown (0)

Patricia Cappuyns (0)

Claire Purkiss (0)

Katie Rooth (0)

Katrin Gutsmiedl (0)

Matthew Raynor (0)

David Nilsson (0)

Leigh-Anne Thomas (0)

Gabriel Cuonzo (0)

Manuel Wegrostek (0)

Jan Zillies (0)

Amy Cullen (0)

Benjamin Bai (0)

Gregory Bacon (0)

Isabelle Romet (0)

Mathilda Nordmark (0)

Luke McDonagh (0)

Begoña González Otero (0)

Kluwer Patent Blog (0)

Anton Polikarpov (0)

Jan Lindberg (0)

Gerben Hartman (0)

Rien Broekstra (0)

Audrey Nemeth (0)

Daniel Byrne (0)

Adam Flint (0)

Alexandre L. Dias Pereira (0)

Jan Pot (0)

Claire Phipps-Jones (0)

Peter Ling (0)

Paul Marcelis (0)

Thomas Long (0)

Edward L. Puzzo (0)

Mark Engstrom (0)

Jody Coultas (0)

Peter Reap (0)

Åse Røynestad Konsmo (0)

Valerie Eder (0)

Cheryl Beise (0)

Aida Tohala (0)

Brandi O. Brown (0)

Beatriz San Martin (0)

Russell Beck (0)

Greg Hammond (0)

Thomas Hendicott (0)

Krišjānis Bušs (0)

Jan-Diederik Lindemans (0)

Devika Agarwal (0)

Gaëlle Béquet (0)

newgenblog (0)

Beatrice Nybert (0)

Lodewijk Pessers (0)

John Collins (0)

Verena von Bomhard (0)

Patrick Harrison (0)

Vanessa Rieu (0)

Dominic Adair (0)

Alona Kiriak (0)

Allen Dixon (0)

Maria Kendrick (0)

Yuqing Feng (0)

Pierre Heuzé (0)

Linda O'Brien (0)

Frits Michiels (0)

Hui Zhang (0)

Inga Lukauskienė (0)

Adrian Chew (0)

Richard Li (0)

Elisabeth C. Pope (0)

Jiao Yuxin (0)

Jurgen Figys (0)

Yin Li (0)

Laura von Herzen (0)

Nicolaj Bording (0)

James Yang (0)

Annsley Ward (0)

Rachel Mumby (0)

Nigel Swycher (0)

Brian Slater (0)

Emma Muncey (0)

Eszter Szakács (0)

Samuel Adams (0)

Christos Theodoulou (0)

Gregory Sephton (0)

Birgit Kramer (0)

Alan Johnson (0)

Benjamin May (0)

Francois Pochart (0)

Alexander de Leeuw (0)

Laura Reynolds (0)

Dominik Scheible (0)

Volker Tillmann (0)

Boris Malakhov (0)

Sara Moran (0)

Nadja Muncke (0)

Craig Lumb (0)

Joseph Arshawsky (0)

Axel T. Esser (0)

H. Jeremias V. Wollschlaeger (0)

Rebecca Kahn (0)

Roland Schieren (0)

Laurence Lai (0)

Linda Panszczyk (0)

Nicholas Round (0)

Brian Craig (0)

Arnie Clarke (0)

Alexa von Uexküll (0)

Harold S. Berman (0)

Ilarion Tomarov (0)

George Basharis (0)

Oswin Ridderbusch (0)

Bart van Wezenbeek (0)

Wouter Pors (0)

Philipp Widera (0)

Sam Jones (0)

Jan Carl Zilles (0)

Filko Prugo (0)

Simon Michels (0)

Joshua Price (0)

Andrea Sommer (0)

Joost Duijm (0)

Scott King (0)

Boukje van der Maazen (0)

Paul Reiter (0)

Michael Vallance (0)

Matt Pavich (0)

Matthew Rizzolo (0)

Grégoire Desrousseaux (0)

Alex Calver (0)

Nadine Bleach (0)

Selin Sinem Erciyas (0)

Barbara Abegg (0)

Kate O’Sullivan (0)

Leon Li (0)

Aysel Korkmaz Yatkın (0)

Daniel Graetsch (0)

Selina Badiani (0)

James Prankerd Smith (0)

Gemma Wooden (0)

Binxin Li (0)

Enrico Bonadio (0)

Richard Gillespie (0)

Harriet Crawford (0)

Nidhisha Garg (0)

Vaishali Mittal (0)

Ben Millson (0)

Jonathan Ross (0)

Charlotte Jacobsen (0)

Christian Buchholz (0)

Emma Irwin (0)

Thomas K. Lauletta (0)

Matteo Mariano (0)

Roya Ghafele (0)

David Yucht (0)

Kathrin Füchsle (0)

Roberto A. Jacchia (0)

Elizabeth McAuliffe (0)

Bashar H. Malkawi (0)

Alex Latham (0)

Nicole D. Prysby (0)

Pamela C. Maloney (0)

Kaspar Feldmeier (0)

Matthieu Dhenne (0)

Sheri A. Wattles-Miller (0)

Richard Mair (0)

Jiří Slavík (0)

João Pedro Quintais (0)

Fabian Hötzel (0)

Luca Falciola (0)

Olivia Henry (0)

Lisa L. Mueller (0)

Liat Sanz Martinez (0)

Roberto Castro de Figueiredo (0)

Magnus Dahlman (0)

Somto Kizor-Akaraiwe (0)

António Magalhães Cardoso (0)

Neemesh Chheda (0)

Ananta Saxena (0)

Lena Hornkohl (0)

Mike Gruber (0)

Michaela Ring (0)

Felix Briza (0)

Radhi Shah (0)

Naho Ebata (0)

Nick Michelmore (0)

Kevin M. Finson (0)

Florence Plisner (0)

Sophie Britton (0)

Kluwer IP Reporter (0)

Chloe Dickson (0)

Richard Aarons (0)

Dr. Narayan Sircar (0)

William White (0)

Natalie Shoolman (0)

Mami Hino (0)

Christopher Dumont (0)

Gabriel Di Blasi (0)

Rob Rodrigues (0)

David Hemming (0)

Eden Winlow (0)

Friedrich Felix Jacob (0)

Matthew Hersh (0)

Dr. Lisa Rieth (0)

Nina Ferara (0)

Joachim Henkel (0)

Luke Maunder (0)

Callum Beamish (0)

Kirill Osipov (0)

Karlo Tinoco (0)

Lucie Fortune (0)

Kameshwaris Sridhar (0)

Alina Trapova (0)

Ivo Emanuilov (0)

Myles Jelf (0)

Rebekka Thomas (0)

Katie Cambrook (0)

Richard Pinckney (0)

Danilo Ruggero Di Bella (0)

Anne Marie Verschuur (0)

Adam Lacy (0)

Louis Bidaine (0)

Milly Wickson (0)

Liz Cohen (0)

Rebecca Daramola (0)

Charlie French (0)

Francion Brooks (0)

Jonathan Santman (0)

Jasmijn de Groot (0)

Hannah Rigby (0)

Naomi Hazenberg (0)

Hafsa Babar (0)

Dr. Malte Köllner (0)

Dr. Carlota Vergas Romero (0)

James Boon (0)

Dr. Alex Frank (0)

Laura Durán (0)

Eveline Lots (0)

Tilman Müller-Stoy (0)

Malin Malm Waerme (0)

Nischay Mall (0)

Prof. Dr. Aloys Hüttermann (0)

Joana Piriquito Santos (0)

Georgii Stoiko (0)

Christophe Arfan, Associate and UPC Representative (0)

Date

From

To

End date must be later than the start date.

Search Results for:

194 results available

191 - 194 of 194 results

About Kluwer Patent Blog
Contact Us

Wolters Kluwer: IP Law
Wolters Kluwer: X
YouTube

Editorial Policy & Guidelines
Privacy Policy and Use of Cookies
User Agreement and Disclaimer